Optimization of the use of ciprofloxacin

Pathologie Biologie

Volumn 57, Issue 3, 2009, Pages 236-239

  Aubert, G ^a   Carricajo, A ^a   Fonsale, N ^a   Vautrin, A C ^a  

^a HÔPITAL NORD   (France)

Author keywords

Ciprofloxacin; E. coli; Mutant prevention concentration; Time killing curve

Indexed keywords

CIPROFLOXACIN;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG UTILIZATION; EPSILOMETER TEST; ESCHERICHIA COLI; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; GYRA GENE; GYRB GENE; MARR GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PARE GENE; POLYMERASE CHAIN REACTION;

ANTI-INFECTIVE AGENTS; CELL DIVISION; CIPROFLOXACIN; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE AMPLIFICATION; HUMANS; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; POLYMERASE CHAIN REACTION;

EID: 64949159770     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.12.005     Document Type: Article

References (16)

1. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornself B., et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 279 (1998) 125-129
2. Zelenitsky S.A., Harding G.K.M., Sun S., Ubhi K., and Ariano R.E. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52 (2003) 668-674
3. Blondeau J., Zhao X., Hansen G., and Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45 (2001) 433-438
4. Drlica K., and Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 44 (2007) 681-688
5. Drusano G.L., Johnson D., Rosen M., and Standiford H. Pharmacodynamic of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 40 Suppl. A (1993) 35-43
6. National Committee for Clinical and Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents: tentative guideline M26-T. NCCLS, Villanova, PA, 1992.
7. Lindgren P.K., Karlson A., and Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infection. Antimicrob Agents Chemother 47 (2003) 3222-3232
8. Nordman P., and Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 56 (2005) 463-469
9. Zhanel G.G., Hisanaga T.L., Laing L.M., Decorby M.R., Nichol K.A., Weshnoweski B., et al., NAUTICA Group. Antibiotic resistance in Escherichia coli outpatient urinary isolates; final results from the north American urinary tract infection collaborative alliance (NAUTICA). Int J Antimicrob Agents 27 (2006) 468-475
10. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
11. Gonzalez M.A., Moranchel A.H., Duran S., Pichardo A., Magana J.L., Painter B., et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 28 (1985) 235-239
12. Lippman J., Scribante J., Gous A.G., Hon H., and Tshukutsoane. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 42 (1998) 2235-2239
13. Kahlmeter G., Brown D.F., Golstein F., MacGowan A.P., Mouton J.W., Osterlund A., et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrobial Chemother 52 (2003) 145-148
14. Zhao X., Eisner W., Perl-Rosentham N., Kreiswirth B., and Drlica K. Mutant prevention concentration of garinoxacin (BMS-284756) for ciprofloxacin-susceptible or resistant Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1023-1027
15. Marcusson L., Olofsson S., Lindgren P.K., Cars O., and Hughes D. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55 (2005) 938-943
16. Drlica K., Zhao X., Blondeau J.M., and Hesje C. Low correlation between MIC and mutant prevention concentrations. Antimicrobial Agents Chemother 50 (2006) 403-404